Correlation of hsa miR-101-5p and hsa miR-155-3p Expression With c-Fos in Patients of Oral Submucous Fibrosis (OSMF) and Oral Squamous Cell Carcinoma (OSCC)
© The Association of Oral and Maxillofacial Surgeons of India 2021..
Aim: MicroRNAs have been widely acknowledged as a diagnostic, prognostic, and/or therapeutic biomarker for the progression of OSCC, but the correlation of hsa-miR-101-5p and hsa-miR-155-3p is yet to be established with c-Fos in OSCC and OSMF.
Methodology: An observational study enrolled 40 patients divided into 2 groups: Group I-21 OSMF patients without malignant transformation, Group II-19 patients with locally advanced, large-operable, or metastatic OSCC, after applying inclusion and exclusion criteria. Both miRNAs were extracted and analyzed from the tissue sample excised from the involved site. The linear regression analysis of the expression of hsa-miR-155-3p, hsa-miR-101-5p, and levels of c-fos in OSMF and OSCC patients and its correlation for habits, age, and gender were evaluated.
Results: The expression of hsa-miR-101-5p was 0.81 times downregulated in OSCC tissue compared to OSMF, whereas hsa-miR-155-3p and c-fos were both upregulated 9.30 times and 1.75 times, respectively, in OSCC tissue. In Gutkha and tobacco chewers, the hsa-miR-155-3p expression could explain 12.3% (p = 0.031) for Gutkha chewers, whereas c-fos could explain 38.6% of the cases (p = 0.020) for tobacco chewers. The expression of hsa-miR-101-5p and hsa-miR-155-3p explained 43.7% and 59.5% of OSCC cases in alcoholics, respectively. Interestingly, in non-alcoholics, hsa-miR-155-3p and hsa-miR-101-5p were significant predictors of OSCC.
Conclusion: Downregulation of tumor-suppressor hsa-miR-101-5p and upregulation of proto-onco hsa-miR-155-3p is responsible for intricate regulation of the progression of OSMF to OSCC via deregulated expression of c-Fos and tobacco chewing and advancing age is significant contributors for OSCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of maxillofacial and oral surgery - 22(2023), 2 vom: 14. Juni, Seite 381-387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chugh, Ankita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C-fos |
|---|
| Anmerkungen: |
Date Revised 02.05.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12663-021-01668-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356261875 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356261875 | ||
| 003 | DE-627 | ||
| 005 | 20231226210318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12663-021-01668-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356261875 | ||
| 035 | |a (NLM)37122804 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chugh, Ankita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correlation of hsa miR-101-5p and hsa miR-155-3p Expression With c-Fos in Patients of Oral Submucous Fibrosis (OSMF) and Oral Squamous Cell Carcinoma (OSCC) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Association of Oral and Maxillofacial Surgeons of India 2021. | ||
| 520 | |a Aim: MicroRNAs have been widely acknowledged as a diagnostic, prognostic, and/or therapeutic biomarker for the progression of OSCC, but the correlation of hsa-miR-101-5p and hsa-miR-155-3p is yet to be established with c-Fos in OSCC and OSMF | ||
| 520 | |a Methodology: An observational study enrolled 40 patients divided into 2 groups: Group I-21 OSMF patients without malignant transformation, Group II-19 patients with locally advanced, large-operable, or metastatic OSCC, after applying inclusion and exclusion criteria. Both miRNAs were extracted and analyzed from the tissue sample excised from the involved site. The linear regression analysis of the expression of hsa-miR-155-3p, hsa-miR-101-5p, and levels of c-fos in OSMF and OSCC patients and its correlation for habits, age, and gender were evaluated | ||
| 520 | |a Results: The expression of hsa-miR-101-5p was 0.81 times downregulated in OSCC tissue compared to OSMF, whereas hsa-miR-155-3p and c-fos were both upregulated 9.30 times and 1.75 times, respectively, in OSCC tissue. In Gutkha and tobacco chewers, the hsa-miR-155-3p expression could explain 12.3% (p = 0.031) for Gutkha chewers, whereas c-fos could explain 38.6% of the cases (p = 0.020) for tobacco chewers. The expression of hsa-miR-101-5p and hsa-miR-155-3p explained 43.7% and 59.5% of OSCC cases in alcoholics, respectively. Interestingly, in non-alcoholics, hsa-miR-155-3p and hsa-miR-101-5p were significant predictors of OSCC | ||
| 520 | |a Conclusion: Downregulation of tumor-suppressor hsa-miR-101-5p and upregulation of proto-onco hsa-miR-155-3p is responsible for intricate regulation of the progression of OSMF to OSCC via deregulated expression of c-Fos and tobacco chewing and advancing age is significant contributors for OSCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Oral Squamous cell carcinoma | |
| 650 | 4 | |a Oral submucous fibrosis | |
| 650 | 4 | |a c-fos | |
| 650 | 4 | |a hsa-miR-101-5p | |
| 650 | 4 | |a hsa-miR-155-3p | |
| 650 | 4 | |a microRNA | |
| 700 | 1 | |a Purohit, Purvi |e verfasserin |4 aut | |
| 700 | 1 | |a Vishnoi, Jeewan Ram |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Amanjot |e verfasserin |4 aut | |
| 700 | 1 | |a Modi, Anupama |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Sanjeev |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Praveen |e verfasserin |4 aut | |
| 700 | 1 | |a Rodha, Mahaveer Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Pareek, Puneet |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Shilajit |e verfasserin |4 aut | |
| 700 | 1 | |a Gigi, P G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of maxillofacial and oral surgery |d 2009 |g 22(2023), 2 vom: 14. Juni, Seite 381-387 |w (DE-627)NLM215840992 |x 0972-8279 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:2 |g day:14 |g month:06 |g pages:381-387 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12663-021-01668-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 2 |b 14 |c 06 |h 381-387 | ||